ReviewCurrent oncology reports2017
Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress.
Review in Current oncology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 61 citations in OpenAlex.
- Pheochromocytomas and Paragangliomas-Current Management.Cancers · 2025Review
- Imaging of Pheochromocytomas and Paragangliomas.Endocrine reviews · 2024Review
- The Management of Phaeochromocytomas and Paragangliomas in the Era of Precision Medicine: Where Are We Now? Evidence-Based Systemic Treatment Options and Future Cluster Oriented Perspectives.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Surgical Treatment of Spinal Metastatic Pheochromocytoma and Paraganglioma: A Single Institutional Cohort of 18 Patients.Global spine journal · 2023Article
- Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options.Cancer medicine · 2023Review
- Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience.Journal of endocrinological investigation · 2022Article
- New Directions in Treatment of Metastatic or Advanced Pheochromocytomas and Sympathetic Paragangliomas: an American, Contemporary, Pragmatic Approach.Current oncology reports · 2022Review
- Neuroendocrine neoplasia and bone (Review).Experimental and therapeutic medicine · 2021Review
- Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT.Current oncology (Toronto, Ont.) · 2021Article
- Malignant pheochromocytoma with cerebral and skull metastasis: A case report and literature review.World journal of clinical cases · 2021Article
- Clinical Perspectives of Theranostics.Molecules (Basel, Switzerland) · 2021Review
- Metastatic Paraganglioma of the Spine WithInternational journal of spine surgery · 2021Article
- Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview.Journal of endocrinological investigation · 2021Review
- Collet-Sicard Syndrome as the Presentation of Malignant Pheochromocytoma.The Neurohospitalist · 2020Article
- Clinical features and prognosis analysis of metastatic spinal pheochromocytoma: A single center retrospective study.Journal of bone oncology · 2020Article
- Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma.Current treatment options in oncology · 2020Review
- Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.The Journal of clinical endocrinology and metabolism · 2020Article
- A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature.Frontiers in endocrinology · 2020Article
- Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine.Cancers · 2019Review
- Surgical treatment of malignant paraganglioma with spinal invasion in a juvenile patient: A case report.Medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe purpose of this manuscript is to review the progress in the field of therapeutics for malignant pheochromocytomas and sympathetic paraganglioma (MPPG) over the past 5 years. RECENT
findingsThe manuscript will describe the clinical predictors of survivorship and their influence on the first TNM staging classification for pheochromocytomas and sympathetic paragangliomas, the treatment of hormonal complications, and the rationale that supports the resection of the primary tumor and metastases in patients with otherwise incurable disease. Therapeutic options for patients with bone metastasis to the spine will be presented. The manuscript will also review chemotherapy and propose a maintenance regimen with dacarbazine for patients initially treated with cyclophosphamide, vincristine, and dacarbazine. Finally, the manuscript will review preliminary results of several phase 2 clinical trials of novel radiopharmaceutical agents and tyrosine kinase inhibitors. MPPGs are very rare neuroendocrine tumors. MPPGs are usually characterized by a large tumor burden, excessive secretion of catecholamines, and decreased overall survival. Recent discoveries have enhanced our knowledge of the pathogenesis and phenotypes of MPPG. This knowledge is leading to a better understanding of the indications and limitations of the currently available localized and systemic therapies as well as the development of phase 2 clinical trials for novel medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.